Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice.

摘要: Effective control of non-small-cell lung cancer (NSCLC) remains clinically challenging, especially during advanced stages the disease. This study developed an adoptive T-cell treatment through expression a chimeric antigen receptor (CAR) to target human epidermal growth factor (EGFR) in NSCLC. We optimized non-viral piggyBac transposon system engineer T cells for EGFR-CAR, consisting EGFR scFv, transmembrane domain, and intracellular 4-1BB-CD3ζ signaling domains. The modified CAR exhibited expansion capability anticancer efficacy time- antigen-dependent manner vitro as well regression EGFR-positive xenografts vivo. EGFR-CAR therapy is promising strategy improve potency immunotherapy Moreover, could become clinical application NSCLC patients future.